Bektur, C.Nurgozhin, T.2017-12-132017-12-132014-11-01C. Bektur, T. Nurgozhin, PMS17 - Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in Kazakhstan, In Value in Health, Volume 17, Issue 7, 2014, Pages A773-A77410983015https://www.sciencedirect.com/science/article/pii/S1098301514022633http://nur.nu.edu.kz/handle/123456789/2874A phase III clinical trial demonstrated the advantage of denosumab over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA became available. The purpose of this study was to examine the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC.ArticleCopyright © 2014 Published by Elsevier Inc.